Biocon shares fell 2% to Rs 361.5 after the USFDA issued four observations following an inspection of its Bengaluru API facility. The compa...

Biocon Biologics received EMA approval to manufacture biosimilar Bevacizumab in Bengaluru, providing additional capacity to address patient...

Biocon Biologics has announced that its insulin manufacturing facility in Johor, Malaysia has been classified as an official action indicat...

The US drug regulator issued 6 observations for drug substance, drug product units and quality Control laboratories and 2 observations for ...

“We are investing thoughtfully to expand the global footprint step by step across the world. We have opened regional offices across Latin A...

The company won a patent litigation initiated by Sanofi for the Insulin Glargine device.

Here is a lowdown of the movers and shakers of Wednesday’s session on Dalal Street.

“This is to inform you that Biocon Sdn Bhd, a subsidiary of Biocon, has received the EIR from the USFDA for the pre-approval inspection of ...

Access in healthcare medication is a big concern globally and insulin prices have been soaring in recent years.

Biocon is confident of addressing these observations through a corrective and preventive action plan in a timely manner, it added.

US health regulator has issued 12 observations after the inspection of three of Biocon's units in Malaysia.

Here is a list of top stocks that are likely to be in focus in today's trading session.

Here's a lowdown on top macro triggers that may move market on Thursday

Total investments by Indian firms overseas rose by 58.6 per cent to $2.19 billion in August this year over the same month last year.

According to CCM, Malaysia’s anti-diabetic market is growing at 10.6 per cent annually. In 2011, it was worth RM 277 million.

Indian biotech companies are increasingly looking to make major investments in Malaysia, lured by the south-east Asian country's tax sops.

The four Indians featuring in Forbes' list of Asia Pacific's most generous business personalities this year are all women. Savvy girls in t...